CIM101: Feeder cells for NK cell expansion

CiMaas can provide the F012 Feeder cell to interested parties seeking rapid NK cell expansion from various sources under licensing conditions. The F012 clone is manufactured in a B-grade cleanroom under GMP conditions and underwent comprehensive characterization to ensure it is free from adventitious viruses, mycoplasma, and other contaminants, making it suitable for clinical NK cell manufacturing applications.

F012 is available as irradiated product, as well as a non-irradiated (patented) product that has been treated differently. Both treatments results in identical expansion rates of NK cells and are completely absent in the final NK cell product.

CIM201: Adoptive NK cell therapy

Secondly, CiMaas has developed an NK cell product. The expansion technology functions as a platform for treatment of many types of cancer. Currently, we are capable of expanding NK cells 5.000-10.000 fold in 12 days with our proprietary technology using the in house generated feeder cells. The cytotoxicity of these cells is very high, even after a freeze/thaw cycle. 

CIM401: Adoptive CAR-NK cell therapy (Solid tumors)

To further improve NK cell activity, CiMaas develops Chimeric Antigen Receptor (CAR)-NK cells for solid tumors. Toxicity of CAR-NK cells is expected to be lower than CAR-T cells. The CARs are directed against tumor-specific underglycosylated proteins. The first focus is on breast cancer, but can be applied in many solid tumors.

Cellular Immunotherapy in development:

Watch the video